GC Biopharma, Sanofi to jointly market Plavix

GC Biopharma Co. (formerly Green Cross Corp.) said on Monday it has entered into a joint sales partnership with Sanofi-Aventis Korea, the South Korean subsidiary of multinational pharmaceuticals company Sanofi, for Plavix 75 mg, an antiplatelet medication.

The agreement calls for GC Biopharma to take charge of the sales and marketing of Plavix, focusing primarily on domestic clinics.

Plavix is an antiplatelet drug prescribed for patients who have suffered a stroke, myocardial infarction or peripheral arterial disease.

"We are committed to continuing our cooperation with initiatives such as open innovation and joint sales partnerships to provide various treatment options for managing the risk factors of chronic diseases in Korea," said an official from GC Biopharma.

Write to Jung-Eun Kim at likesmile@hankyung.com